Latest Low-density lipoprotein Stories

Largest study of LDL blood levels, based on tests of nearly 105 million Americans, suggests improvements in cardiovascular health may have stalled in recent years MADISON, N.J., May 13, 2013 /PRNewswire/ -- Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE. The study, by researchers at Quest Diagnostics (NYSE: DGX),...

Michael Harper for redOrbit.com – Your Universe Online Doctors have long considered many nuts to be quite heart healthy. The fatty acids found in nuts along with high doses of fiber and vitamins are thought to reduce the levels of LDL, or “bad” cholesterol in the blood. Now, a team of Penn State researchers are parroting other studies that have found walnuts to be one of the healthiest nuts there is. “We already know that eating walnuts in a heart-healthy diet can lower blood...

WOODBRIDGE, ON, May 7, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, presented positive, statistically significant, top-line results from its VASCAZEN(®)-REVEAL trial for the Company's lead product VASCAZEN(®), a unique >90% pure Omega-3 prescription medical food with a proprietary 6:1 EPA:DHA fatty acid formulation. The results...

redOrbit Staff & Wire Reports - Your Universe Online Liptruzet, a combination drug developed by Merck that has been found to lower a patient’s low-density lipoprotein (LDL) cholesterol levels, has been approved by the US Food and Drug Administration (FDA). According to MedPage Today Cardiology Editor Chris Kaiser, Liptruzet is a combination of the drugs ezetimibe and atorvastatin and has been approved for the treatment of hyperlipidemia, a condition characterized by abnormally...

Many of the genes regulating the inflammation and immune response of the body are also associated with low HDL-cholesterol levels in the circulation, tells the recent study conducted at the University of Helsinki, Finland. The research also discovered that the quality of HDL particle can vary considerably. Cholesterol is a major risk factor for heart disease. Elevated LDL-cholesterol, commonly known as the 'bad cholesterol,' is associated with increased risk of heart disease while...

WOODBRIDGE, ON, April 30, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it will be presenting its top line results from its recently concluded clinical trial, at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013 Scientific Sessions to be held in Lake Buena Vista,...

Michael Harper for redOrbit.com – Your Universe Online Multiple studies have concluded high amounts of cholesterol can be damaging to your heart and can, in turn, lead to Alzheimer’s disease or stroke. Though this single fact has been well documented, the exact reason why high cholesterol affects the brain has been largely unclear for many years. Researchers from the Linda Crnic Institute for Down Syndrome and the University of Colorado School of Medicine have studied this link and...

redOrbit Staff & Wire Reports - Your Universe Online Researchers from the University of Michigan (UMich) have found a new genetic target which they believe could be used instead of -- or along with -- statins to help lower a person’s cholesterol. Scientists working in the lab of David Ginsburg at the Ann Arbor-based university’s Life Sciences Institute managed to inhibit the action of a gene responsible for transporting a protein known to interfere with the liver’s ability to...

WOODBRIDGE, ON, April 9, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that VASCAZEN(®) met its primary endpoint in the REVEAL trial. Additionally, VASCAZEN(®) achieved statistical significance in various secondary endpoints in patients presenting with elevated triglycerides (>200mg/dL < 500mg/dL). The...

Published, Third-Party Clinical Study Confirms Beachbody Ultimate Reset® Health Claims LOS ANGELES, April 8, 2013 /PRNewswire/ -- Beachbody®, the health-and-fitness pioneer behind popular home-exercise programs and effective nutritional solutions, today announced that a research study by the prestigious New York Chiropractic College has validated the efficacy of its Ultimate Reset® 21-Day cleanse program. The results, gathered from this peer reviewed and published third-party...